LOS ANGELES, Oct. 18, 2024 – Investors holding OM shares now have a chance to spearhead the securities turmoil action against Outset Medical, Inc. (“Outset Medical” or the “Company”).
Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024
The case suggests that during the Class Period, Outset Medical’s administrators hid crucial details from investors regarding the Tablo products. These products were advertised for continuous renal replacement therapy, which hadn’t received FDA approval, potentially leading to an additional 510(k) application. The complaint also mentions risks of a halt in Tablo sales, sales team insufficiencies, and consequential harm to revenue growth. Consequently, the Company’s optimistic assertions regarding its business operations were arguably deceptive.
To be a part of the legal proceedings, shareholders are not obligated to act at this moment. They can select legal counsel or opt for non-intervention and remain a passive participant. For clarification on this lawsuit, individuals can reach out to Frank R. Cruz at The Law Offices of Frank R. Cruz or visit their website.
This lawsuit signifies the need for investors to stay vigilant and well-informed about corporate operations to protect their financial interests.